Japanese drugmaker Takeda has officially announced positive top-line readouts from a head-to-head clinical trial, demonstrating that its investigational autoimmune candidate, zasocitinib, bested Bristol Myers Squibb’s commercialized therapy, Sotyktu, in patients presenting with plaque psoriasis. While detailed analytical datasets remain undisclosed, Takeda confirmed that zasocitinib established statistical superiority over Sotyktu across all primary and secondary therapeutic goals, validating corporate confidence regarding the asset’s downstream competitive advantages.
The documented PASI clinical efficacy metrics, market segment positioning, and R&D portfolio strategy feature:
-
Superior Clinical Efficacy Metrics Over Standard-of-Care Sotyktu:
-
PASI 100 Cleansing Thresholds: Following a 16-week treatment architecture, zasocitinib successfully eliminated all visible skin lesions in 35% of treated recipients, achieving the benchmark for complete skin clearance known as PASI 100. This efficacy readout is 2.5-times higher than the performance logged by the Sotyktu cohort, satisfying the primary objective of the protocol with robust statistical significance. For context, in legacy registration trials run by Bristol Myers, up to 14% of trial enrollees reached the PASI 100 milestone.
-
Secondary Target Performance: Zasocitinib additionally outpaced Sotyktu across all secondary clinical endpoints, including sub-total skin clearance measurements such as PASI 90 and PASI 75 responses. This data marks the second consecutive instance where Takeda’s small molecule has defeated a validated competitor, following a previous head-to-head trial victory against Amgen’s Otezla.
-
-
Commercial Positioning and Challenges From Injectable Biologics:
-
Sotyktu Market Deficits: Sotyktu operated as the first-in-class TYK2 inhibitor to capture U.S. Food and Drug Administration (FDA) approval. However, the pill has struggled to build commercial momentum, generating a modest $291 million in global revenue over fiscal year 2025. Despite an impending regulatory green light in psoriatic arthritis, Bristol Myers recently revealed blueprints to halt the active promotion of Sotyktu within the dermatology space across multiple geographic territories, driven by a broad clinical preference among dermatologists for high-efficacy injectable biologics.
-
Takeda’s Market Capitalization Strategy: Takeda CEO-elect Julie Kim asserted that the advanced oral therapeutic segment represents the fastest-growing market vector, with patient volumes expected to triple over the coming decade. Takeda positions zasocitinib to reshape treatment expectations as a premier oral intervention for plaque psoriasis. Nevertheless, analysts note that zasocitinib’s standalone PASI 100 velocity still falls short of milestones set by injectable blockbusters such as AbbVie’s Skyrizi and J&J’s Tremfya, against which it has not been directly evaluated.
-
-
High-Stakes Capital Asset Sourcing and Future Clinical Horizons:
-
Takeda onboarded zasocitinib via a high-stakes $4 billion upfront corporate acquisition from Nimbus Therapeutics, initiating a series of comparative trials to secure its market foothold.
-
The molecule is close to entering a highly saturated market landscape featuring established blockbusters alongside novel candidates, such as an upcoming oral option from Johnson & Johnson. A critical near-term valuation catalyst for the asset is a major upcoming data readout in inflammatory bowel disease (IBD) slated for late 2026. This evaluation carries high technical risk, given that two legacy TYK2 inhibitors, including Sotyktu, previously failed to satisfy clinical goals in registration studies for ulcerative colitis or Crohn’s disease.
-
Source: https://www.biopharmadive.com/news/takeda-zasocitinib-sotyktu-psoriasis-trial/822500/